U.S. markets open in 1 hour 26 minutes

Acrux Limited (ARUXF)

OTC Markets OTCPK - OTC Markets OTCPK Precio retrasado. Moneda en USD.
Añadir a la lista de seguimiento
0.0306-0.0046 (-13.07%)
Al cierre: 02:26PM EDT

Acrux Limited

103-113, Stanley Street
West Melbourne, VIC 3003
Australia
61 3 8379 0100
https://www.acrux.com.au

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo

Descripción

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Gestión corporativa

La calificación ISS Governance QuickScore de Acrux Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.